Andersen, Okay. G. et al. Scientific sequencing uncovers origins and evolution of Lassa virus. Cell 162, 738–750 (2015).
Pinneo, L. & Pinneo, R. Thriller virus from Lassa. Am. J. Nurs. 71, 1352–1355 (1971).
Watts, G. M. Lily Lyman Pinneo. Lancet 380, 1552 (2013).
Leifer, E., Gocke, D. J. & Bourne, H. Lassa fever, a brand new virus illness of man from West Africa. II. Report of a laboratory-acquired an infection handled with plasma from an individual lately recovered from the illness. Am. J. Trop. Med. Hyg. 19, 677–679 (1970).
Buckley, S. M., Casals, J. & Downs, W. G. Isolation and antigenic characterization of Lassa virus. Nature 227, 174 (1970). This work reviews the preliminary isolation and characterization of Lassa virus.
Buckley, S. M. & Casals, J. Lassa fever, a brand new virus illness of man from West Africa. 3. Isolation and characterization of the virus. Am. J. Trop. Med. Hyg. 19, 680–691 (1970).
Monath, T. P., Newhouse, V. F., Kemp, G. E., Setzer, H. W. & Cacciapuoti, A. Lassa virus isolation from Mastomys natalensis rodents throughout an epidemic in Sierra Leone. Science 185, 263–265 (1974). This work is the primary demonstration that Lassa virus is rodent-borne.
Fichet-Calvet, E., Becker-Ziaja, B., Koivogui, L. & Gunther, S. Lassa serology in pure populations of rodents and horizontal transmission. Vector Borne Zoonotic Dis. 14, 665–674 (2014).
Fichet-Calvet, E., Lecompte, E., Koivogui, L., Daffis, S. & ter Meulen, J. Reproductive traits of Mastomys natalensis and Lassa virus prevalence in Guinea, West Africa. Vector Borne Zoonotic Dis. 8, 41–48 (2008).
Kakaī, C. G. et al. Enhancing cross-border preparedness and response: classes discovered from 3 lassa fever outbreaks throughout Benin, Nigeria, and Togo, 2017–2019. Well being Secur. 18, S105–S112 (2020).
Patassi, A. A. et al. Emergence of lassa fever illness in northern Togo: report of two instances in Oti district in 2016. Case Rep. Infect. Dis. 2017, 8242313 (2017).
Sogoba, N., Feldmann, H. & Safronetz, D. Lassa fever in West Africa: proof for an expanded area of endemicity. Zoonoses Public Well being 59, 43–47 (2012).
Jahrling, P. B. et al. Lassa virus an infection of rhesus monkeys: pathogenesis and therapy with ribavirin. J. Infect. Dis. 141, 580–589 (1980). This work presents the event of a non-human primate mannequin.
Peters, C. J. et al. Experimental research of arenaviral hemorrhagic fevers. Curr. High. Microbiol. Immunol. 134, 5–68 (1987).
Hartnett, J. N. et al. Present and rising methods for the analysis, prevention and therapy of Lassa fever. Future Virol. 10, 559–584 (2015).
Goba, A. et al. An outbreak of Ebola virus illness within the Lassa fever zone. J. Infect. Dis. https://doi.org/10.1093/infdis/jiw239 (2016).
Cross, R. W. et al. Remedy of Lassa virus an infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antivir. Res. 133, 218–222 (2016). This work presents the preliminary characterization of Lassa virus monoclonal antibodies in animals.
Mire, C. E. et al. Human-monoclonal-antibody remedy protects nonhuman primates in opposition to superior Lassa fever. Nat. Med. 23, 1146–1149 (2017).
Cashman, Okay. A. et al. Analysis of Lassa antiviral compound ST-193 in a guinea pig mannequin. Antivir. Res. 90, 70–79 (2011).
Hansen, F., Jarvis, M. A., Feldmann, H. & Rosenke, Okay. Lassa virus therapy choices. Microorganisms https://doi.org/10.3390/microorganisms9040772 (2021).
Salami, Okay., Gouglas, D., Schmaljohn, C., Saville, M. & Tornieporth, N. A evaluation of Lassa fever vaccine candidates. Curr. Opin. Virol. 37, 105–111 (2019).
Gale, T. V., Horton, T. M., Hoffmann, A. R., Branco, L. M. & Garry, R. F. Host proteins recognized in extracellular viral particles as targets for broad-spectrum antiviral inhibitors. J. Proteome Res. 18, 7–17 (2019).
Rowe, W. P. et al. Arenoviruses: proposed title for a newly outlined virus group. J. Virol. 5, 651–652 (1970).
Oldstone, M. B. Arenaviruses. I. The epidemiology molecular and cell biology of arenaviruses. Introduction. Curr. High. Microbiol. Immunol. 262, V–XII (2002).
Hastie, Okay. M., Kimberlin, C. R., Zandonatti, M. A., MacRae, I. J. & Saphire, E. O. Construction of the Lassa virus nucleoprotein reveals a dsRNA-specific 3′ to five′ exonuclease exercise important for immune suppression. Proc. Natl Acad. Sci. USA 108, 2396–2401 (2011).
Hastie, Okay. M., King, L. B., Zandonatti, M. A. & Saphire, E. O. Structural foundation for the dsRNA specificity of the Lassa virus NP exonuclease. PloS ONE 7, e44211 (2012).
Hastie, Okay. M. et al. Crystal construction of the Lassa virus nucleoprotein–RNA complicated reveals a gating mechanism for RNA binding. Proc. Natl Acad. Sci. USA 108, 19365–19370 (2011).
Hastie, Okay. M. & Saphire, E. O. Lassa virus glycoprotein: stopping a shifting goal. Curr. Opin. Virol. https://doi.org/10.1016/j.coviro.2018.05.002 (2018).
Kouba, T. et al. Conformational modifications in Lassa virus L protein related to promoter binding and RNA synthesis exercise. Nat. Commun. 12, 7018 (2021).
Xu, X. et al. Cryo-EM buildings of Lassa and Machupo virus polymerases complexed with cognate regulatory Z proteins determine targets for antivirals. Nat. Microbiol. 6, 921–931 (2021).
Hastie, Okay. M. et al. Crystal construction of the oligomeric type of Lassa virus matrix protein Z. J. Virol. 90, 4556–4562 (2016).
Joseph, S. & Campbell, Okay. P. Lassa fever virus binds matriglycan-A polymer of alternating xylose and glucuronate-on α-dystroglycan. Viruses https://doi.org/10.3390/v13091679 (2021).
Brouillette, R. B. et al. TIM-1 mediates dystroglycan-independent entry of Lassa virus. J. Virol. https://doi.org/10.1128/jvi.00093-18 (2018).
Fedeli, C., Moreno, H. & Kunz, S. The function of receptor tyrosine kinases in lassa virus cell entry. Viruses https://doi.org/10.3390/v12080857 (2020).
Fedeli, C. et al. Axl can function entry issue for Lassa virus relying on the useful glycosylation of dystroglycan. J. Virol. https://doi.org/10.1128/jvi.01613-17 (2018).
Goncalves, A. R. et al. Position of DC-SIGN in Lassa virus entry into human dendritic cells. J. Virol. 87, 11504–11515 (2013).
Cao, W. et al. Identification of α-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 282, 2079–2081 (1998).
Li, S. et al. Acidic pH-induced conformations and LAMP1 binding of the Lassa virus glycoprotein spike. PloS Pathog. 12, e1005418 (2016).
Israeli, H., Cohen-Dvashi, H., Shulman, A., Shimon, A. & Diskin, R. Mapping of the Lassa virus LAMP1 binding website reveals distinctive determinants not shared by different previous world arenaviruses. PloS Pathog. 13, e1006337 (2017).
Radoshitzky, S. R., Buchmeier, M. J. & de la Torre, J. C. in Subject’s Virology seventh edn Vol. 1 Ch. 18 (eds Howley, P. M. & Knipe, D. M.) (Lippincott Williams & Wilkins, 2020).
Auperin, D. D., Sasso, D. R. & McCormick, J. B. Nucleotide sequence of the glycoprotein gene and intergenic area of the Lassa virus S genome RNA. Virology 154, 155–167 (1986).
Reguera, J. et al. Comparative structural and useful evaluation of Bunyavirus and Arenavirus cap-snatching endonucleases. PloS Pathog. 12, e1005636 (2016).
Hastie, Okay. M. et al. Structural foundation for antibody-mediated neutralization of Lassa virus. Science 356, 923–928 (2017). This work reveals the construction of the native trimeric construction of the Lassa virus glycoprotein.
Lenz, O., ter Meulen, J., Klenk, H. D., Seidah, N. G. & Garten, W. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc. Natl Acad. Sci. USA 98, 12701–12705 (2001).
Yasuda, S. U. & Jiro Molecular mechanism of arenavirus meeting and budding. Viruses 4, 2049–2079 (2012).
Ehichioya, D. U. et al. Phylogeography of Lassa virus in Nigeria. J. Virol. https://doi.org/10.1128/jvi.00929-19 (2019).
Bowen, M. D. et al. Genetic variety amongst Lassa virus strains. J. Virol. 74, 6992–7004 (2000). This work examines Lassa virus phylogeny.
Mofolorunsho, Okay. C. Outbreak of lassa fever in Nigeria: measures for prevention and management. Pan Afr. Med. J. 23, 210 (2016).
Akhiwu, H. O. et al. Lassa fever outbreak in adolescents in north central Nigeria: report of instances. J. Virus Erad. 4, 225–227 (2018).
Akpede, G. O., Asogun, D. A., Okogbenin, S. A. & Okokhere, P. O. Lassa fever outbreaks in Nigeria. Skilled Rev. Anti Infect. Ther. 16, 663–666 (2018).
Ilori, E. A. et al. Epidemiologic and scientific options of Lassa fever outbreak in Nigeria, January 1–Might 6, 2018. Emerg. Infect. Dis. 25, 1066–1074 (2019).
Maxmen, A. Lethal Lassa-fever outbreak assessments Nigeria’s revamped well being company. Nature 555, 421–422 (2018).
Siddle, Okay. J. et al. Genomic evaluation of Lassa virus throughout a rise in instances in Nigeria in 2018. N. Engl. J. Med. 379, 1745–1753 (2018).
Manning, J. T., Forrester, N. & Paessler, S. Lassa virus isolates from Mali and the Ivory Coast symbolize an rising fifth lineage. Entrance. Microbiol. 6, 1037 (2015).
Whitmer, S. L. M. et al. New lineage of Lassa virus, Togo, 2016. Emerg. Infect. Dis. 24, 599–602 (2018).
Boisen, M. L. et al. A number of circulating infections can mimic the early phases of viral hemorrhagic fevers and attainable human publicity to filoviruses in Sierra Leone previous to the 2014 outbreak. Viral Immunol. 28, 19–31 (2015).
Richmond, J. Okay. & Baglole, D. J. Lassa fever: epidemiology, scientific options, and social penalties. BMJ 327, 1271–1275 (2003).
Macher, A. M. & Wolfe, M. S. Historic Lassa fever reviews and 30-year scientific replace. Emerg. Infect. Dis. 12, 835–837 (2006).
Wolf, T., Ellwanger, R., Goetsch, U., Wetzstein, N. & Gottschalk, R. Fifty years of imported Lassa fever–a scientific evaluation of main and secondary instances. J. Journey Med. https://doi.org/10.1093/jtm/taaa035 (2020).
Ehlkes, L. et al. Administration of a Lassa fever outbreak, Rhineland-Palatinate, Germany, 2016. Eur. Surveill. https://doi.org/10.2807/1560-7917.Es.2017.22.39.16-00728 (2017).
Njuguna, C. et al. A difficult response to a Lassa fever outbreak in a non endemic space of Sierra Leone in 2019 with export of instances to The Netherlands. Int. J. Infect. Dis. 117, 295–301 (2022).
WHO. Lassa fever–United Kingdom of Nice Britain and Northern Eire. World Well being Group https://www.who.int/emergencies/disease-outbreak-news/merchandise/lassa-fever-united-kingdom-of-great-britain-and-northern-ireland (2022).
Grange, Z. L. et al. Rating the danger of animal-to-human spillover for newly found viruses. Proc. Natl Acad. Sci. USA 118, e2002324118 (2021).
Smither, A. R. & Bell-Kareem, A. R. Ecology of Lassa virus. Curr. High. Microbiol. Immunol. https://doi.org/10.1007/82_2020_231 (2021).
Shaffer, J. G. et al. Lassa fever in post-conflict Sierra Leone. PloS Negl. Trop. Dis. 8, e2748 (2014).
Bonwitt, J. et al. At dwelling with Mastomys and Rattus: human–rodent interactions and potential for main transmission of Lassa virus in home areas. Am. J. Trop. Med. Hyg. 96, 935–943 (2017).
Bonwitt, J. et al. Rat-atouille: a blended methodology research to characterize rodent searching and consumption within the context of Lassa fever. EcoHealth 13, 234–247 (2016).
Mari Saez, A. et al. Rodent management to combat Lassa fever: analysis and classes discovered from a 4-year research in Higher Guinea. PloS Negl. Trop. Dis. 12, e0006829 (2018).
WHO. Lassa fever. World Well being Group https://www.who.int/health-topics/lassa-fever#tab=tab_1 (2022).
Knobloch, J. et al. Scientific observations in 42 sufferers with Lassa fever. Tropenmed Parasitol. 31, 389–398 (1980).
McCormick, J. B. & Fisher-Hoch, S. P. Lassa fever. Curr. High. Microbiol. Immunol. 262, 75–109 (2002).
Akhuemokhan, O. C. et al. Prevalence of Lassa virus illness (LVD) in Nigerian youngsters with fever or fever and convulsions in an endemic space. PloS Negl. Trop. Dis. 11, e0005711 (2017).
Okokhere, P. et al. Scientific and laboratory predictors of Lassa fever end result in a devoted therapy facility in Nigeria: a retrospective, observational cohort research. Lancet Infect. Dis. 18, 684–695 (2018).
Ehichioya, D. U. et al. Hospital-based surveillance for Lassa fever in Edo State, Nigeria, 2005–2008. Trop. Med. Int. Well being 17, 1001–1004 (2012).
Buba, M. I. et al. Mortality amongst confirmed lassa fever instances in the course of the 2015–2016 outbreak in Nigeria. Am. J. Public Well being 108, 262–264 (2018).
Branco, L. M. et al. Lassa hemorrhagic fever in a late time period being pregnant from northern Sierra Leone with a optimistic maternal end result: case report. Virol. J. 8, 404 (2011).
Okogbenin, S. et al. Retrospective cohort research of Lassa fever in being pregnant, southern Nigeria. Emerg. Infect. Dis. https://doi.org/10.3201/eid2508.181299 (2019).
Ilori, E. A. et al. Improve in Lassa fever instances in Nigeria, January–March 2018. Emerg. Infect. Dis. 25, 1026–1027 (2019).
Ficenec, S. C. et al. Lassa fever induced listening to loss: the uncared for incapacity of hemorrhagic fever. Int. J. Infect. Dis. 100, 82–87 (2020).
Ficenec, S. C., Schieffelin, J. S. & Emmett, S. D. A evaluation of listening to loss related to Zika, Ebola, and Lassa fever. Am. J. Trop. Med. Hyg. 101, 484–490 (2019).
Duvignaud, A. et al. Delayed-onset paraparesis in Lassa fever: a case report. Int. J. Infect. Dis. 92, 49–52 (2020).
Ezeomah, C. et al. Sequelae of Lassa fever: postviral cerebellar ataxia. Open Discussion board Infect. Dis. 6, ofz512 (2019).
Li, A. L. et al. Ophthalmic manifestations and imaginative and prescient impairment in Lassa fever survivors. PloS ONE 15, e0243766 (2020).
Garry, R. F. Ebola virus can lie low and reactivate after years in human survivors. Nature 597, 478–480 (2021).
Lee, H. & Nishiura, H. Recrudescence of Ebola virus illness outbreak in West Africa, 2014–2016. Int. J. Infect. Dis. 64, 90–92 (2017).
McCormick, J. B. et al. Lassa fever. Efficient remedy with ribavirin. N. Engl. J. Med. 314, 20–26 (1986). This work reviews a therapy research with ribavirin in people.
Eberhardt, Okay. A. et al. Ribavirin for the therapy of Lassa fever: a scientific evaluation and meta-analysis. Int. J. Infect. Dis. https://doi.org/10.1016/j.ijid.2019.07.015 (2019).
Salam, A. P. et al. Time to rethink the function of ribavirin in Lassa fever. PloS Negl. Trop. Dis. 15, e0009522 (2021).
Hastie, Okay. M., Bale, S., Kimberlin, C. R. & Saphire, E. O. Hiding the proof: two methods for innate immune evasion by hemorrhagic fever viruses. Curr. Opin. Virol. 2, 151–156 (2012).
Huang, Q., Liu, X., Brisse, M., Ly, H. & Liang, Y. Impact of pressure variations on Lassa virus Z protein-mediated human RIG-I inhibition. Viruses https://doi.org/10.3390/v12090907 (2020).
Watanabe, Y. et al. Construction of the Lassa virus glycan defend offers a mannequin for immunological resistance. Proc. Natl Acad. Sci. USA 115, 7320–7325 (2018).
Branco, L. M. et al. Rising traits in Lassa fever: redefining the function of immunoglobulin M and irritation in diagnosing acute an infection. Virol. J. 8, 478 (2011).
Prescott, J. B. et al. Immunobiology of Ebola and Lassa virus infections. Nat. Rev. Immunol. 17, 195–207 (2017).
Sakabe, S. et al. Identification of frequent CD8+ T cell epitopes from Lassa fever survivors in Nigeria and Sierra Leone. J. Virol. https://doi.org/10.1128/jvi.00153-20 (2020).
Sullivan, B. M. et al. Excessive crossreactivity of human T cell responses between Lassa virus lineages. PloS Pathog. 16, e1008352 (2020).
Botten, J. et al. Identification of protecting Lassa virus epitopes which might be restricted by HLA-A2. J. Virol. 80, 8351–8361 (2006).
Flatz, L. et al. T cell-dependence of Lassa fever pathogenesis. PloS Pathog. 6, e1000836 (2010).
Port, J. R. et al. Extreme human Lassa fever is characterised by nonspecific T-cell activation and lymphocyte homing to infected tissues. J. Virol. https://doi.org/10.1128/jvi.01367-20 (2020).
Asogun, D. A. et al. Molecular diagnostics for lassa fever at Irrua Specialist Instructing Hospital, Nigeria: classes learnt from two years of laboratory operation. PloS Negl. Trop. Dis. 6, e1839 (2012).
Boisen, M. L. et al. Subject validation of recombinant antigen immunoassays for analysis of Lassa fever. Sci. Rep. 8, 5939 (2018).
Boisen, M. L. et al. Subject analysis of a pan-Lassa speedy diagnostic take a look at in the course of the 2018 Nigerian Lassa fever outbreak. Sci. Rep. 10, 8724 (2020).
Heinrich, M. L. et al. Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages. Sci. Rep. 10, 16030 (2020).
Furuta, Y., Komeno, T. & Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 93, 449–463 (2017).
Safronetz, D. et al. The broad-spectrum antiviral favipiravir protects guinea pigs from deadly Lassa virus an infection post-disease onset. Sci. Rep. 5, 14775 (2015).
Oestereich, L. et al. Efficacy of favipiravir alone and together with ribavirin in a deadly, immunocompetent mouse mannequin of Lassa fever. J. Infect. Dis. 213, 934–938 (2016).
Lingas, G., Rosenke, Okay., Safronetz, D. & Guedj, J. Lassa viral dynamics in non-human primates handled with favipiravir or ribavirin. PloS Comput. Biol. 17, e1008535 (2021).
Rosenke, Okay. et al. Use of favipiravir to deal with Lassa virus an infection in macaques. Emerg. Infect. Dis. 24, 1696–1699 (2018).
Mendenhall, M. et al. Efficient oral favipiravir (T-705) remedy initiated after the onset of scientific illness in a mannequin of arenavirus hemorrhagic fever. PloS Negl. Trop. Dis. 5, e1342 (2011).
Gowen, B. B. et al. Assessing modifications in vascular permeability in a hamster mannequin of viral hemorrhagic fever. Virol. J. 7, 240 (2010).
Raabe, V. N. et al. Favipiravir and ribavirin therapy of epidemiologically linked instances of Lassa fever. Clin. Infect. Dis. 65, 855–859 (2017).
Larson, R. A. et al. Identification of a broad-spectrum arenavirus entry inhibitor. J. Virol. 82, 10768–10775 (2008).
Robinson, J. E. et al. Most neutralizing human monoclonal antibodies goal novel epitopes requiring each Lassa virus glycoprotein subunits. Nat. Commun. 7, 11544 (2016).
Cross, R. W. et al. Antibody remedy for Lassa fever. Curr. Opin. Virol. 37, 97–104 (2019).
Hastie, Okay. M. et al. Convergent buildings illuminate options for germline antibody binding and pan-Lassa virus neutralization. Cell 178, 1004–1015.e14 (2019).
Buck, T. Okay. et al. Neutralizing antibodies in opposition to lassa virus lineage I. mBio https://doi.org/10.1128/mbio.01278-22 (2022).
White, J. M. et al. Drug mixtures as a primary line of protection in opposition to coronaviruses and different rising viruses. mBio 12, e0334721 (2021).
Johnson, D. M., Cubitt, B., Pfeffer, T. L., de la Torre, J. C. & Lukashevich, I. S. Lassa virus vaccine candidate ML29 generates truncated viral RNAs which contribute to interfering exercise and attenuation. Viruses https://doi.org/10.3390/v13020214 (2021).
Cashman, Okay. A. et al. A DNA vaccine delivered by dermal electroporation absolutely protects cynomolgus macaques in opposition to Lassa fever. Hum. Vaccines Immunother. 13, 2902–2911 (2017).
Cross, R. W. et al. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and dying. J. Clin. Make investments. 130, 539–551 (2020).
Stein, D. R. et al. A recombinant vesicular stomatitis-based Lassa fever vaccine elicits speedy and long-term safety from deadly Lassa virus an infection in guinea pigs. NPJ Vaccines 4, 8 (2019).
Abreu-Mota, T. et al. Non-neutralizing antibodies elicited by recombinant Lassa–rabies vaccine are essential for cover in opposition to Lassa fever. Nat. Commun. 9, 4223 (2018).
Mateo, M. et al. A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys in opposition to heterologous strains. Sci. Transl Med. https://doi.org/10.1126/scitranslmed.abf6348 (2021).
Salvato, M. S. et al. A single dose of modified vaccinia ankara expressing Lassa virus-like particles protects mice from deadly intra-cerebral virus problem. Pathogens https://doi.org/10.3390/pathogens8030133 (2019).
Wang, M. et al. Development and immunological analysis of an adenoviral vector-based vaccine candidate for Lassa fever. Viruses https://doi.org/10.3390/v13030484 (2021).
Fischer, R. J. et al. ChAdOx1-vectored Lassa fever vaccine elicits a sturdy mobile and humoral immune response and protects guinea pigs in opposition to deadly Lassa virus problem. NPJ Vaccines 6, 32 (2021).
Müller, H. et al. Adjuvant formulated virus-like particles expressing native-like types of the Lassa virus envelope floor glycoprotein are immunogenic and induce antibodies with broadly neutralizing exercise. NPJ Vaccines 5, 71 (2020).
Branco, L. M. et al. Lassa virus-like particles displaying all main immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol. J. 7, 279 (2010).
Kainulainen, M. H. et al. Safety from deadly Lassa illness could be achieved each earlier than and after virus publicity by administration of single-cycle replicating Lassa virus replicon particles. J. Infect. Dis. 220, 1281–1289 (2019).
Gouglas, D., Christodoulou, M., Plotkin, S. A. & Hatchett, R. CEPI: driving progress towards epidemic preparedness and response. Epidemiol. Rev. 41, 28–33 (2019).
Koch, M. R. et al. Well being in search of conduct after the 2013–16 Ebola epidemic: Lassa fever as a metric of persistent modifications in Kenema District, Sierra Leone. PloS Negl. Trop. Dis. 15, e0009576 (2021).
Meyer, B. & Ly, H. Inhibition of innate immune responses is vital to pathogenesis by arenaviruses. J. Virol. 90, 3810–3818 (2016).
